Electronic database, Google Scholar, and a WHO website were searched with keywords such as EMPA, SGLT-2 inhibitor, prediabetic and nondiabetic, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), hepatic lipid metabolism, IR, hepatic steatosis, and obesity. Here, SLC5A2 is linked to metabolic dysfunction-associated steatohepatitis.